GNI Group Ltd. announced that the Company has agreed to enter into two transactions with Catalyst Biosciences, Inc. to advance development of F351 for liver fibrosis in US, Europe and Japan. The above two transactions do not affect Continent's main business. Continent continues to own F351 rights in mainland China and will continue on-going clinical developments including Phase III clinical trials for HBV-induced liver fibrosis.

Continent will also continue manufacturing and marketing ETUARY(r) in China. Following these two transactions, the Group will be a majority shareholder of CBIO and Continent and will consolidate financial results of CBIO and Continent.